The approval was based on a cohort of treatment-naïve patients in the Beamion LUNG-1 trial who had unresectable or metastatic, non-squamous NSCLC with HER2 tyrosine kinase domain mutations.
News-Medical.Net on MSN
How somatic mutations shape disease and reveal new drug targets
By Tarun Sai Lomte Scientists reveal how evolution within our own tissues can drive disease, protect cells, and uncover hidden therapeutic targets for future precision medicine. Somatic genomics ...
The FDA on Friday granted accelerated approval to zongertinib (Hernexeos) for non-squamous non-small cell lung cancer (NSCLC) patients harboring HER2 tyrosine kinase domain (TKD) activating mutations.
The FDA has granted accelerated approval to zongertinib (Hernexeos; Boehringer Ingelheim Pharmaceuticals, Inc.) for adults with unresectable or metastatic non-squamous non–small cell lung cancer ...
The Commissioner’s National Priority Voucher pilot program enabled rolling review, enhanced FDA interaction, and a rapid 44-day decision, alongside breakthrough therapy and priority review ...
Morning Overview on MSN
How gene mutations disrupt cell growth and trigger cancer?
Cancer begins when mutations in specific genes override the body’s built-in controls on cell division, allowing rogue cells ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results